The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin

Young-In Kim1,2 | Rajat Pareek1,2 | Ryan Murphy1,3 | Lisa Harrison1,2 | Eric Farrell1 | Robert Cook4 | John DeVincenzo1,2,3,5

1Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA
2Children’s Foundation Research Institute at Le Bonheur Children’s Hospital, Memphis, TN, USA
3College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
4Teva Global Respiratory R&D, Teva Pharmaceuticals, Monmouth Junction, NJ, USA
5Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA

Background: Respiratory syncytial virus (RSV) viral load and disease severity associate, and the timing of viral load and disease run in parallel. An antiviral must be broadly effective against the natural spectrum of RSV genotypes and must attain concentrations capable of inhibiting viral replication within the human respiratory tract.

Objectives: We evaluated a novel RSV fusion inhibitor, MDT-637, and compared it with ribavirin for therapeutic effect in vitro to identify relative therapeutic doses achievable in humans.

Method: MDT-637 and ribavirin were co-incubated with RSV in HEp-2 cells. Quantitative PCR assessed viral concentrations; 50% inhibitory concentrations (IC50) were compared to achievable human MDT-637 and ribavirin peak and trough concentrations.

Results and conclusions: The IC50 for MDT-637 and ribavirin (against RSV-A Long) was 1.42 and 16 973 ng/mL, respectively. The ratio of achievable peak respiratory secretion concentration to IC50 was 6041-fold for MDT-637 and 25-fold for aerosolized ribavirin. The ratio of trough concentration to IC50 was 1481-fold for MDT-637 and 3.29-fold for aerosolized ribavirin. Maximal peak and trough levels of oral or intravenous ribavirin were significantly lower than their IC50s. We also measured MDT-637 IC50s in 3 lab strains and 4 clinical strains. The IC50s ranged from 0.36 to 3.4 ng/mL. Achievable human MDT-637 concentrations in respiratory secretions exceed the IC50 by factors from hundreds to thousands of times greater than does ribavirin. Furthermore, MDT-637 has broad in vitro antiviral activity on clinical strains of different RSV genotypes and clades. Together, these data imply that MDT-637 may produce a superior clinical effect compared to ribavirin on natural RSV infections.

KEYWORDS
- antiviral
- bronchiolitis
- fusion inhibitor
- pharmacokinetics
- respiratory syncytial virus
- ribavirin
Respiratory syncytial virus (RSV) causes acute bronchiolitis and pneumonia, which are important causes of childhood illness and death. Every year ~3% of all US infants are hospitalized with RSV infection most of whom are previously healthy. The burden of RSV in outpatients is even greater with ~39% of all outpatient visits under 2 years of age caused by this virus. Treatment with nebulized beta-2 agonists, epinephrine, Heliox, or surfactant has been studied. But, the trials have either not shown convincing clinical benefit or offer very short-term benefit, which does not alter the underlying disease process. Corticosteroids have not shown benefit and increase the concentration of RSV in the respiratory tract. Nebulized hypertonic saline has also not shown benefit. Ribavirin inhibits RSV replication and is the only FDA-approved specific treatment for RSV lower respiratory tract infection. Aerosolized ribavirin has been demonstrated to achieve inhibition of viral load within 2 hours. Intravenous and oral ribavirin have never been adequately dosed either continuously or for three, dosing times each day, each lasting 2 hours. Intravenous and oral ribavirin have never been adequately studied for RSV therapy. No licensed vaccines currently exist for pre-empting RSV infections. Prophylactic administration of monoclonal antibodies has been effective in reducing, but not eliminating, severe RSV disease, and this antibody is only recommended for under 3% of the birth cohort in the United States. Therapeutic uses of high potency RSV-monoclonal antibody have not shown clinical benefit. The pediatric population needs an efficient and easily applied therapy for RSV.

More potent RSV antivirals are promising because higher viral loads and greater disease severity correlate in infants and more rapid natural clearance of RSV and shorter hospital stays correlate. Furthermore, we have recently shown that the timing of RSV load and disease track together. This implies that reducing viral load may translate into clinical benefit. Even at a time when viral replication is at its highest, application of antiviral agents early in the disease course might improve subsequent morbidity by significantly lowering viral load, reducing direct viral cytopathic effects, and aborting potential downstream immunopathology.

A major consideration for candidate experimental RSV antivirals is the requirement that the molecule is broadly active across the natural spectrum of viral genotypes. The RSV G protein, which mediates viral attachment to target cells, is the most genetically and antigenically diverse RSV protein and forms the basis of genotyping. We have retained a series of primary low-passage isolates from a broad clade range including genotypes RSV-A and RSV-B (Fig. S1). Antiviral activity of any new therapeutic must be preserved across this wide range of diverse RSV isolates.

MDT-637 (previously called VP14637, Teva Pharmaceuticals, Tel Aviv, Israel) is a substituted bis-tetrazole-benzhydryl phenol, which has been reported to reduce RSV replication by inhibition of the F-protein function. This molecule has produced an antiviral effect in vivo (cotton rats) following delivery by small droplet aerosol. It has been reformulated so as to be deliverable to humans. A phase-1 evaluation of single and multiple ascending doses of aerosolized MDT-637 to determine its safety and pharmacokinetics has been completed (ClinicalTrials.gov identifier NCT01475305).

We therefore evaluated the in vitro antiviral effects of MDT-637 (50% inhibitory concentration, IC<sub>50</sub>) against a broad range of genetically diverse RSV strains and compared it to ribavirin. We also related the IC<sub>50</sub> of MDT-637 and ribavirin to the concentrations achieved within human respiratory secretions so as to evaluate the relative antiviral effect in humans infected with community-acquired RSV.

### MATERIALS AND METHODS

#### Cells and viruses

Human epithelial carcinoma (HEp-2) cells (ATCC, CCL-23) were used for RSV replication in the presence of MDT-637 or ribavirin. RSV-A Long (ATCC, VR-26) and A2 (ATCC, VR-1540) and RSV-9320 (ATCC, VR-955) were maintained by serial passage in the laboratory. A broad range of RSV clinical isolates (RSV-Memphis-37, RSV-LAP0824, RSV-HAN1135; Fig. S1) representative of the major clades of RSV-A and RSV-B was selected for this study. This study was conducted with the approval of the Institutional Review Board of the University of Tennessee Health Science Center.

#### Compounds

MDT-637 (MicroDose Therapeutix Inc., NJ, USA) was solubilized in 5 mL of 100% dimethylsulfoxide. Consecutive 10-fold serial dilutions subsequently were prepared with DMEM until the first experimental drug concentration (0.1 μmol/L) was reached. Half-log dilutions were then performed with DMEM from 0.1 μmol/L to 31.6 pmol/L. Ribavirin (Calbiochem, CA, USA) was diluted using the same serial dilution as described for MDT-637.

#### Exposure of RSV to Drug

The laboratory and clinical isolates of RSV (Multiplicity of Infection [MOI]; 0.001) and various concentrations (ranging from 0.1 μmol/L...
to 31.6 pmol/L) of MDT-637 (or ribavirin) were added to the HEp-2 cell monolayers at the same time. After 72 hours of incubation at 37°C, the cells and supernatants were harvested. An aliquot was immediately serially diluted and used for plaque assay as described in section “Quantification by Culture.” The remainder cell-supernatant mixture was frozen at −80°C and subsequently quantified by qPCR.

2.4 | Quantification by culture (qCx)

Plaque assays were performed as previously described using the human RSV-A Long strain (for A strains) and RSV-B, 9320 (for B strains) as a quantitative standard.

2.5 | Quantitative real-time-PCR (qPCR)

Viral RNA was extracted from the samples frozen at −80°C using QIAsymphony Virus/Bacteria Mini/Midi Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions and incubated with DNA-free DNase (TURBO DNA-free Kit, Applied Biosystems, Foster City, CA). The viral RNA extraction used the QIAsymphony Pathogen Complex 400 Protocol on the QIAsymphony Viral Extractor Robot (Serial No. 10502). Following extraction, cDNA was obtained through reverse transcription using the QIAGEN Omniscript RT Kit (QIAGEN, Valencia) and N gene-specific custom primers (Applied Biosystems, Foster City, CA). PCR was performed as previously described.

2.6 | Statistics

All statistical analyses were performed using GRAPHPAD PRISM, Version 5.0d.

3 | RESULTS

3.1 | Comparison of the in vitro antiviral effect of MDT-637 to ribavirin

The IC₅₀s for MDT-637 and ribavirin against RSV-A Long were 1.42 ng/mL and 16 973 ng/mL by qPCR, respectively. By qCulture, the IC₅₀s were 1.83 ng/mL for MDT-637 and 20 509 ng/mL for ribavirin. These represent over 11 000-fold greater potency of MDT-637 (Table 1 and Figure 1).

3.2 | In vitro antiviral effect of MDT-637 against broad range of RSV isolates

MTD-637 IC₅₀s were measured with three laboratory strains (RSV-A Long, RSV-A2, and RSV-9320) and three clinical strains (RSV-Memphis-37, RSV-LAP0824, and RSV-HAN1135; Fig. S1). The IC₅₀s ranged from 0.36 to 3.4 ng/mL measured by qPCR (Table 2). IC₅₀s were measured by qCx for RSV strains, A Long, A2, and Memphis-37, and correlated with the corresponding IC₅₀s measured by qPCR validating the fidelity of the two measurement techniques (Table S1). For subsequent strains, antiviral effect was measured only by the qPCR.

3.3 | MTD-637 concentrations in human respiratory secretions compared to IC₅₀s

MTD-637 has poor aqueous solubility and approximately 180-fold greater solubility in simulated lung fluid. In a phase I clinical trial (ClinicalTrials.gov identifier NCT01475305), after safely receiving aerosolized MDT-637, concentrations in saline nasal washes were measured, then extrapolated using this solubility factor and compared to the MDT-637 IC₅₀s obtained for RSV-A Long and RSV-Memphis-37. Peak extrapolated MDT-637 concentrations were over 6,000-fold greater than the IC₅₀s (Table 3).
3.4 | Ratios of achievable concentrations of RSV antivirals to their corresponding IC$_{50}$s

Using RSV-A Long, the ratio of achievable peak respiratory secretion concentration to IC$_{50}$ was 6,041-fold for MDT-637 and 25-fold for ribavirin. The ratio of trough concentration to IC$_{50}$ was 1,481-fold for MDT-637 and 3.29-fold for ribavirin (Table 4).

4 | DISCUSSION

Treatment options for RSV are suboptimal. In search of effective antivirals, the RSV F-protein has emerged as an active target. Multiple novel small compounds acting as RSV entry inhibitors by targeting the F protein have been studied. Many of them have demonstrated potent in vitro antiviral effects. We have completed preclinical and early clinical studies for several of these compounds.$^{31,32}$

Ribavirin, a nucleoside analogue (anti-RSV small molecule), is the only FDA-approved RSV therapeutic. But, it has questionable and limited antiviral efficacy and almost no clinical use in current times. However, it offers a standard to which new therapeutics can be compared. Previous antiviral effect comparison studies have been performed between ribavirin and MDT-637. Douglas et al have demonstrated the in vitro antiviral effects of MDT-637 and ribavirin using cytopathic effect-inhibitory assay.$^{24}$ Their cytopathic effect assay showed a 50% effective concentration (EC$_{50}$) for MDT-637.
was 1.4 nmol/L (or 0.715 ng/mL), whereas the EC$_{50}$ for ribavirin was 33 000 nmol/L (or 16 847 ng/mL) against the RSV-A2 strain. Wyde et al demonstrated the antiviral effect of MDT-637 and ribavirin against RSV-A Long and the EC$_{50}$ were 0.001 ± 0.004 μmol/L (or 0.51 ± 2.04 ng/mL) and 20 ± 10 μmol/L (or 10,210 ± 5,105 ng/mL), respectively. These studies demonstrated MDT-637 was over 20 000-fold more potent than ribavirin. In the present study, we have shown IC$_{50}$ for MDT-637 against RSV-A Long and RSV-A2 were 1.83 ng/mL and 2.708 ng/mL, respectively (by qCx), and 1.42 ng/mL and 3.4 ng/mL, respectively (by qPCR). We also compared the in vitro antiviral effects of MDT-637 to ribavirin against RSV-A Long strain. In line with previously reported data, our data support that MDT-637 is over 11 000-fold more potent than ribavirin in vitro (IC$_{50}$ ribavirin 20 509 ng/mL [qCx] and 16 973 ng/mL [qPCR]). Our findings are in line with previously reported data.

We extended these findings to evaluate activity across a series of RSV low passage, strains representing a broad range of genotypic diversity. Our clinical isolates represented the major clades of both RSV-A and RSV-B to show that MDT-637 retains antiviral effects against the wide range of RSV genotypes. The IC$_{50}$ of MDT-637 ranged from 0.36 to 3.4 ng/mL (qPCR). These strain-specific differences are small and are unlikely to affect the activity of MDT-637 given the high achievable respiratory tract concentration. Similar RSV strain differences in fusion inhibitor activity have been previously reported.

The extent to which the achievable human concentration of an antiviral exceeds its in vitro inhibitory level can predict its clinical efficacy. We therefore related the IC$_{50}$s to the concentration of MDT-637 and ribavirin achieved in human respiratory secretions. Pharmacokinetic and pharmacodynamics studies of MDT-637 in healthy human volunteers measured the mean drug concentrations in the nasal saline washes at 0.25 hours (peak) and 6 hours (trough) after exposure with 66 μg or 132 μg TID. The mean peak and trough concentrations were 47.66 ng/mL and 11.68 ng/mL, respectively. The mean peak and trough coefficient of variation were 98.40% and 157.32%, respectively. Moreover, however, MDT-637 has poor aqueous solubility; it is about 1/180th that of its solubility in water. Comparing IC$_{50}$ to achievable human drug concentrations predicts that MDT-637 may produce a superior clinical effect compared to ribavirin on natural human RSV infections.

5 | CONCLUSIONS

This study looking at the antiviral effects of the RSV F-protein inhibitor MDT-637 shows that MDT-637 appears to have antiviral activity against laboratory and clinical strains representing broad RSV genetic diversity. It is from several hundred- to thousand-fold more potent in vitro compared to ribavirin. MDT-637 concentrations achievable in human nasal washes are from hundred- to thousand-fold higher than the IC$_{50}$, suggesting that an antiviral effect may be achievable in human. Comparing IC$_{50}$ to achievable human drug concentrations predicts that MDT-637 may produce a superior clinical effect compared to ribavirin on natural human RSV infections.

ACKNOWLEDGEMENTS

We are grateful to the Children’s Foundation Research Institute (CFRI) Small Grant and the Division of Pediatric Critical Care Medicine, University of Tennessee Health Science Center, Memphis TN for funding this study.

ORCID

Young-In Kim http://orcid.org/0000-0003-3215-2685

REFERENCES

1. Boyce TG, Mellen BG, Mitchell Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-598.
3. Abul-Ainine A, Luyt D. Short term effects of adrenaline in bronchiolitis: a randomised controlled trial. Arch Dis Child. 2002;86:276-279.
4. Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 2003;123:481-487.
5. Gross MF, Spear RM, Peterson BM. Helium-oxygen mixture does not improve gas exchange in mechanically ventilated children with bronchiolitis. Crit Care. 2000;4:188-192.
6. Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics. 2002;109:68-73.
7. Tibby SM, Hatherill M, Wright SM, Wilson P, Postle AD, Murdoch IA. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2000;162:1251-1256.
8. Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357:331-339.

9. Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis. 2002;185:1222-1228.

10. Jacobs JD, Foster M, Wang J, Pershad J. 7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial. Pediatrics. 2014;133:e8-e13.

11. Wyde PR, Wilson SZ, Petrella R, Gilbert BE. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 1987;7:211-220.

12. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985;254:3047-3051.

13. Devincenzo JP. Therapy of respiratory syncytial virus infection. Pediatr Infect Dis J. 2000;19:786-790; discussion 802-784, 811-783.

14. Krilov LR, Weiner LB, Yoge R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatr. 2009;124:1682-1684.

15. Malley R, Devincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178:1555-1561.

16. Devincenzo JP, Atitken J, Harrison L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSF fusion protein monoclonal antibody. J Pediatr. 2003;143:123-126.

17. Ramilo O, Lagos R, Saez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33:703-709.

18. Devincenzo JP, El Saleeb MY, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191:1861-1868.

19. El Saleeb MY, Bush AJ, Harrison LM, Atitken J, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011;204:996-1002.

20. Devincenzo JP, Wilkinson T, Vaisnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182:1305-1314.

21. Devincenzo JP. A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer. J Infect Dis. 2007;195:1084-1086.

22. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195:1126-1136.

23. Alvarez R, Claiborne S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009;53:3952-3962.

24. Douglas JS, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP:14637 via specific interactions with F protein. J Virol. 2003;77:5054-5064.

25. Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, Pevear DC. Antiviral efficacy of VP:14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005;68:18-26.

26. Perkins SM, Webb DL, Torrance SA, et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol. 2005;43:2356-2362.

27. Devincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004;56:914-917.

28. Dennis NA, Blauer HM, Kent JE. Dissolution fractions and half-times of single source yellowcake in simulated lung fluids. Health Phys. 1982;42:469-477.

29. Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36:447-448.

30. Cook RO, Reynolds ER, Boris S, Zegar Sl. Compositions and methods for treating or preventing pneumovirus infection and associated diseases. Microdose Therapeutics, Inc. US 2014. US 2014/0005239 A1. 514/381

31. Devincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371:711-722.

32. Devincenzo JP, Mcclure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373:2048-2058.

33. Mackman RL, Sangi M, Sperandio D, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58:1630-1643.

34. Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2015;60:1264-1273.

35. Englund JA, Piedra PA, Jefferson LS, Wilson ZS, Taber LH, Gilbert BE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1990;117:313-320.

36. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40:2555-2557.

37. Khanna N, Widmer AF, Decke M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402-412.

38. Khakoo S, Glue P, Grelle L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 1998;46:563-570.

39. Merck & Co. I. REBETOL® (ribavirin USP) capsules, for oral use, REBETOL® (ribavirin USP) oral solution. 2013.

40. Schering Corporation. REBETOL® (ribavirin, USP) Capsules. 2001.

41. Lertora JJ, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1991;50:442-449.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Kim Y-I, Pareek R, Murphy R, et al. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respi Viruses. 2017;11:525–530. https://doi.org/10.1111/irv.12503